Repeated stellate ganglion blockade for the treatment of ventricular tachycardia storm in patients with nonischemic cardiomyopathy: a new therapeutic option for patients with malignant arrhythmias.
10.3760/cma.j.cn112148-20220525-00411
- Author:
Chang CUI
1
;
Xiao Kai ZHOU
2
;
Yue ZHU
1
;
You Mei SHEN
1
;
Lin Dou CHEN
1
;
Wei Zhu JU
1
;
Hong Wu CHEN
1
;
Kai GU
1
;
Ming Fang LI
1
;
Yin Bing PAN
2
;
Ming Long CHEN
1
Author Information
1. Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
2. Department of Anaesthesiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Male;
Adult;
Middle Aged;
Aged;
Female;
Stroke Volume;
Stellate Ganglion/surgery*;
Ventricular Function, Left;
Cardiomyopathies/complications*;
Tachycardia, Ventricular/therapy*;
Treatment Outcome;
Catheter Ablation
- From:
Chinese Journal of Cardiology
2023;51(5):521-525
- CountryChina
- Language:Chinese
-
Abstract:
Objectives: This study sought to describe our institutional experience of repeated percutaneous stellate ganglion blockade (R-SGB) as a treatment option for drug-refractory electrical storm in patients with nonischemic cardiomyopathy (NICM). Methods: This prospective observational study included 8 consecutive NICM patients who had drug-refractory electrical storm and underwent R-SGB between June 1, 2021 and January 31, 2022. Lidocaine (5 ml, 1%) was injected in the vicinity of the left stellate ganglion under the guidance of ultrasound, once per day for 7 days. Data including clinical characteristics, immediate and long-term outcomes, and procedure related complications were collected. Results: The mean age was (51.5±13.6) years. All patients were male. 5 patients were diagnosed as dilated cardiomyopathy, 2 patients as arrhythmogenic right ventricular cardiomyopathy and 1 patient as hypertrophic cardiomyopathy. The left ventricular ejection fraction was 37.8%±6.6%. After the treatment of R-SGB, 6 (75%) patients were free of electrical storm. 24 hours Holter monitoring showed significant reduction in ventricular tachycardia (VT) episodes from 43.0 (13.3, 276.3) to 1.0 (0.3, 34.0) on the first day following R-SGB (P<0.05) and 0.5 (0.0, 19.3) after whole R-SGB process (P<0.05). There were no procedure-related major complications. The mean follow-up was (4.8±1.1) months, and the median time of recurrent VT was 2 months. Conclusion: Minimally invasive R-SGB is a safe and effective method to treat electrical storm in patients with NICM.
